Physician profile
Melody Pairo
NPI 1528048824
$2,561.68
in general payments reported to CMS, 2019-2025
30 companies · $605 in 2025
The $605 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $356 · 2023: $407 · 2024: $1,007 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,998.75 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $576.64 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $232.66 | 2021-2025 | |
| Lilly USA, LLC | $210.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $210.25 | 2024-2025 | |
| Exact Sciences Corporation | $185.63 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $172.66 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.08 | 2022-2025 | |
| Astellas Pharma US INC | $85.53 | 2023-2024 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $83.23 | 2023-2025 | Farxiga, Breztri |
| Dexcom, INC. | $68.24 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $66.02 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.09 | 2022-2024 | Jardiance, Tradjenta |
| Amgen INC. | $51.35 | 2024 | Repatha, Otezla, Krystexxa |
| Idorsia Pharmaceuticals US INC | $47.57 | 2024 | Quviviq |
| Inspire Medical Systems, INC. | $45.36 | 2025 | Inspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.67 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $28.99 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $27.76 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $27.59 | 2023 | Seglentis |
| Linus Health, INC. | $23.07 | 2023 | |
| Gilead Sciences, INC. | $22.93 | 2025 | |
| Glaxosmithkline, LLC. | $22.85 | 2022 | |
| Global Blood Therapeutics, INC. | $20.13 | 2021 | |
| Becton, Dickinson and Company | $20.10 | 2025 | Bd Max System, Bd Max Instrument |
| E.R. Squibb & Sons, L.L.C. | $20.05 | 2024 | Camzyos |
| Tactile Systems Technology INC | $19.93 | 2025 | Nimbl, Flexitouch Plus |
| Amarin Pharma, INC. | $17.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.06 | 2021 | |
| Evofem Biosciences, INC. | $16.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Pairo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.